公开(公告)号：US20220073580A1

公开(公告)日：2022-03-10

申请号：US17364410

申请日：2021-06-30

Applicant: Monash University ,  Hudson Institute of Medical Research

Inventor： Marcel Nold ,  Claudia Nold ,  Andrew Ellisdon ,  James Whisstock

IPC: C07K14/54 ,  A61P29/00

Abstract: This invention relates to polypeptides, including variants of interleukin-37 (IL-37), and related therapeutics and compositions. The invention also relates to the use of the polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric anti-inflammatory polypeptide comprising an amino acid sequence of an IL-37 monomer, the amino acid sequence having a mutation or modification for preventing the anti-inflammatory peptide from forming a homodimer.

公开(公告)号：US20180162918A1

公开(公告)日：2018-06-14

申请号：US15737204

申请日：2016-06-15

Applicant: Monash University ,  Hudson Institute of Medical Research

Inventor： Marcel Nold ,  Claudia Nold ,  Andrew Ellisdon ,  James Whisstock

IPC: C07K14/54 ,  A61P29/00

CPC classification number: C07K14/54 ,  A61K38/00 ,  A61P29/00

Abstract: This invention relates to polypeptides, including variants of interleukin-37 (IL-37), and related therapeutics and compositions. The invention also relates to the use of the polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric anti-inflammatory polypeptide comprising an amino acid sequence of an IL-37 monomer, the amino acid sequence having a mutation or modification for preventing the anti-inflammatory peptide from forming a homodimer.

公开(公告)号：US20250034222A1

公开(公告)日：2025-01-30

申请号：US18717170

申请日：2022-12-07

Applicant: Monash University ,  HUdson Institute of Medical Research

Inventor： Claudia Annelie Nold ,  Andrew Malcolm Ellisdon ,  Marcel Friedrich Nold ,  James Whisstock

IPC: C07K14/54 ,  A61K38/00 ,  A61P29/00 ,  A61P37/06 ,  C12N15/70

Abstract: This invention relates to polypeptides, including variants of interleukin-38 (IL-38), and related therapeutics and compositions. The invention also relates to the use of the polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric polypeptide comprising an amino acid sequence of an IL-38 monomer, the amino acid sequence having a mutation or modification for preventing the peptide from forming a homodimer and favouring the formation of a stable monomer.

公开(公告)号：US20230220112A1

公开(公告)日：2023-07-13

申请号：US17772090

申请日：2020-10-28

Applicant: MONASH UNIVERSITY

Inventor： James Whisstock ,  Ruby Law ,  Adam Quek ,  Paul Conroy ,  Guojie Wu

IPC: C07K16/40 ,  A61P7/00

CPC classification number: C07K16/40 ,  A61P7/00 ,  C07K2317/92 ,  C07K2317/567 ,  C07K2317/565

Abstract: The present invention provides an antigen binding protein comprising an antigen binding domain that binds to plasmin, wherein the antigen binding protein reduces the activity of plasmin. The invention also provides compositions comprising the antigen binding protein, and uses and method of treatment comprising the same.

公开(公告)号：US20220267751A1

公开(公告)日：2022-08-25

申请号：US17626168

申请日：2020-07-10

Applicant: Monash University

Inventor： James Whisstock ,  Ruby Law ,  Adam Quek ,  Paul Conroy

IPC: C12N9/68 ,  C07K14/81

Abstract: The present invention relates to methods of producing recombinant plasminogen in a mammalian expression system. A method for producing plasminogen, the method comprising (i) providing a host cell comprising a first recombinant polynucleotide encoding plasminogen and a second recombinant polynucleotide encoding a plasminogen activation inhibitor; (ii) culturing said host cell in a suitable culture medium under conditions to effect expression of plasminogen from the first polynucleotide and plasminogen activation inhibitor from the second polynucleotide.

公开(公告)号：US20220380484A1

公开(公告)日：2022-12-01

申请号：US17771982

申请日：2020-10-28

Applicant: Monash University

Inventor： James Whisstock ,  Ruby Law ,  Adam Quek ,  Paul Conroy ,  Dena Lyras ,  Guojie Wu

IPC: C07K16/40 ,  A61P7/04

Abstract: The present invention relates to antigen binding proteins comprising an antigen binding domain that binds to plasminogen, wherein the antigen binding protein reduces the activation of plasminogen to plasmin, pharmaceutical compositions comprising the same, and methods and uses thereof.

公开(公告)号：US11084855B2

公开(公告)日：2021-08-10

申请号：US15737204

申请日：2016-06-15

Applicant: Monash University ,  Hudson Institute of Medical Research

Inventor： Marcel Nold ,  Claudia Nold ,  Andrew Ellisdon ,  James Whisstock

IPC: A61K38/20 ,  A61K38/00 ,  C07K14/54 ,  A61P29/00

Abstract: This invention relates to polypeptides, including variants of interleukin-37 (IL-37), and related therapeutics and compositions. The invention also relates to the use of the polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric anti-inflammatory polypeptide comprising an amino acid sequence of an IL-37 monomer, the amino acid sequence having a mutation or modification for preventing the anti-inflammatory peptide from forming a homodimer.

公开(公告)号：US20190352390A1

公开(公告)日：2019-11-21

申请号：US16471431

申请日：2017-12-22

Applicant: Monash University ,  Hudson Institute of Medical Research

Inventor： Andrew Ellisdon ,  James Whisstock ,  Claudia Nold ,  Marcel Nold

IPC: C07K16/24 ,  G01N33/68

Abstract: The invention relates to IL-37, to antibodies and related fragments thereof for binding to IL-37, to production of said antibodies and fragments and to use of said antibodies and fragments for detection and therapy of various conditions. For example, the invention relates to an antigen binding site that binds to or specifically binds to IL-37 and inhibits IL-37 activity.